These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 34680128)

  • 1. Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant.
    Pascarella S; Ciccozzi M; Bianchi M; Benvenuto D; Giovanetti M; Cauda R; Cassone A
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Isaeva OI; Ketelaars SLC; Kvistborg P
    Front Immunol; 2022; 13():891524. PubMed ID: 35572563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance.
    Kimura I; Kosugi Y; Wu J; Zahradnik J; Yamasoba D; Butlertanaka EP; Tanaka YL; Uriu K; Liu Y; Morizako N; Shirakawa K; Kazuma Y; Nomura R; Horisawa Y; Tokunaga K; Ueno T; Takaori-Kondo A; Schreiber G; Arase H; ; Motozono C; Saito A; Nakagawa S; Sato K
    Cell Rep; 2022 Jan; 38(2):110218. PubMed ID: 34968415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 neutralizing antibody epitopes are overlapping and highly mutated which raises the chances of escape variants and requires development of broadly reactive vaccines.
    Joseph J; Darpe S; Kulkarni G; Raj VS
    Proteins; 2023 Aug; 91(8):1021-1031. PubMed ID: 36912191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8
    Qiu C; Xiao C; Wang Z; Zhu G; Mao L; Chen X; Gao L; Deng J; Su J; Su H; Fang EF; Zhang ZJ; Zhang J; Xie C; Yuan J; Luo OJ; Huang LA; Wang P; Chen G
    Front Immunol; 2021; 12():764949. PubMed ID: 35116022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding.
    Bozdaganyan ME; Shaitan KV; Kirpichnikov MP; Sokolova OS; Orekhov PS
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycan Masking of Epitopes in the NTD and RBD of the Spike Protein Elicits Broadly Neutralizing Antibodies Against SARS-CoV-2 Variants.
    Lin WS; Chen IC; Chen HC; Lee YC; Wu SC
    Front Immunol; 2021; 12():795741. PubMed ID: 34925381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidome Surveillance Across Evolving SARS-CoV-2 Lineages Reveals HLA Binding Conservation in Nucleocapsid Among Variants With Most Potential for T-Cell Epitope Loss in Spike.
    Wnuk K; Sudol J; Spilman P; Soon-Shiong P
    Front Immunol; 2022; 13():918928. PubMed ID: 35812370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Platform for Producing Recombinant Protein Components of Epitope Vaccines for the Prevention of COVID-19.
    Karyagina AS; Gromov AV; Grunina TM; Lyaschuk AM; Grishin AV; Strukova NV; Generalova MS; Galushkina ZM; Soboleva LA; Dobrinina OY; Bolshakova TN; Subbotina ME; Romanovskaya-Romanko EA; Krasilnikov IV; Polyakov NB; Solovyev AI; Grumov DA; Zhukhovitsky VG; Ryabova EI; Prokofiev VV; Lunin VG
    Biochemistry (Mosc); 2021 Oct; 86(10):1275-1287. PubMed ID: 34903153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic surveillance of the Lambda SARS-CoV-2 variant in a global phylogenetic context.
    Mestanza O; Lizarraga W; Padilla-Rojas C; Jimenez-Vasquez V; Hurtado V; Molina IS; Barcena L; Acedo S; Nuñez A; Gordillo S; Sevilla N; Medrano P; Bailon H; Cáceres O; Galarza M; Rojas-Serrano N; Vargas-Herrera N; Lope-Pari P; Huayra J; Araujo-Castillo RV; Solari L
    J Med Virol; 2022 Oct; 94(10):4689-4695. PubMed ID: 35644902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Receptor Binding Domain of SARS-CoV-2 Lambda Variant Has a Better Chance Than the Delta Variant in Evading BNT162b2 COVID-19 mRNA Vaccine-Induced Humoral Immunity.
    Liu H; Wei P; Aviszus K; Zhang Q; Linderberger J; Yang J; Liu J; Chen Z; Waheed H; Reynoso L; Downey GP; Frankel SK; Kappler JW; Marrack P; Zhang G
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introduction of SARS-CoV-2 C.37 (WHO VOI lambda) in the Sao Paulo State, Southeast Brazil.
    Kashima S; Slavov SN; Giovanetti M; Rodrigues ES; Patané JSL; Viala VL; Santos EV; Evaristo M; de Lima LPO; Martins AJ; Dos Santos Barros CR; Marqueze EC; Garibaldi PMM; Ferreira NN; Moraes GR; Brassaloti RA; Cassano RLRC; Mariani PDSC; Kitajima JP; Schlesinger D; Bezerra RS; Assato PA; da Costa FAS; Poleti MD; Lesbon JCC; Mattos EC; Banho CA; Sacchetto L; Grotto RMT; Souza-Neto JA; Fonseca V; de Alcantara LCJ; Nogueira ML; Fukumasu H; Coutinho LL; Borges M; Calado RT; Elias MC; Sampaio SC; Covas DT
    J Med Virol; 2022 Mar; 94(3):1206-1211. PubMed ID: 34647634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resilience of Spike-Specific Immunity Induced by COVID-19 Vaccines against SARS-CoV-2 Variants.
    Ballesteros-Sanabria L; Pelaez-Prestel HF; Ras-Carmona A; Reche PA
    Biomedicines; 2022 Apr; 10(5):. PubMed ID: 35625733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach.
    Uttamrao PP; Sathyaseelan C; Patro LPP; Rathinavelan T
    Front Immunol; 2021; 12():692937. PubMed ID: 34497604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics.
    Chauhan D; Chakravarty N; Jeyachandran AV; Jayakarunakaran A; Sinha S; Mishra R; Arumugaswami V; Ramaiah A
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain.
    Ip JD; Kok KH; Chan WM; Chu AW; Wu WL; Yip CC; To WK; Tsang OT; Leung WS; Chik TS; Chan KH; Hung IF; Yuen KY; To KK
    Clin Microbiol Infect; 2021 Sep; 27(9):1350.e1-1350.e5. PubMed ID: 33144203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.